Table 3 Comparison of treatment outcomes for pediatric non-T ALL treated with a contemporary protocol.

From: Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02

 

n

% EFS (years)

% OS (years)

JACLS ALL-02

1138

84.8 (4)

91.2 (4)

 NCI-SR

815

88.2 (4)

94.5 (4)

 NCI-HR

323

76.4 (4)

83.1 (4)

 1–9 years

923

87.5 (4)

94 (4)

 10–18 years

215

73.4 (4)

79.8 (4)

JACLS ALL-97

566

77 (10)

87 (10)

 NCI-SR

383

81.3 (4)

95 (4)

 NCI-HR

179

71.0 (4)

86.6 (4)

BFM2000

4016

80.4 (7)

91.8 (7)

BFM95

1798

80.2 (6)

 

 NCI-SR

1256

86.5 (6)

 

 NCI-HR

512

67.4 (6)

 

St. Jude Total XV

 NCI-SR

258

89.7 (5)

97.7 (5)

 NCI-HR

164

82.4 (5)

89.7 (5)

NOPHO ALL2008

 1–9 years

1022

89 (5)

94 (5)

 10–17 years

266

80 (5)

87 (5)

TCCSG L04-16

 

80.1 (5)

91.9 (5)

 NCI-SR

646

82.9 (5)

94.2 (5)

 NCI-HR

265

73.2 (5)

86.2 (5)

  1. EFS event-free survival, OS overall survival, JACLS Japan Association of Childhood Leukemia Study Group, NCI National Cancer Institute, SR standard risk, HR high risk, BFM Berlin–Frankfurt–Munster, NOPHO Nordic Society for Pediatric Hematology and Oncology, TCCSG Tokyo Children’s Cancer Study Group.
Back to article page